β-pinene ameliorates ICV-STZ induced Alzheimer's pathology via antioxidant, anticholinesterase, and mitochondrial protective effects: In-silico and in-vivo studies

IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY European journal of pharmacology Pub Date : 2025-03-15 Epub Date: 2025-01-25 DOI:10.1016/j.ejphar.2025.177307
Mini Dahiya , Anil Kumar , Monu Yadav , Shilpi Chauhan
{"title":"β-pinene ameliorates ICV-STZ induced Alzheimer's pathology via antioxidant, anticholinesterase, and mitochondrial protective effects: In-silico and in-vivo studies","authors":"Mini Dahiya ,&nbsp;Anil Kumar ,&nbsp;Monu Yadav ,&nbsp;Shilpi Chauhan","doi":"10.1016/j.ejphar.2025.177307","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Alzheimer's disease (AD) is a leading cause of dementia, characterized by progressive neurodegeneration and cognitive dysfunction. The disease aetiology is closely associated with proteinopathies, mitochondrial abnormalities, and elevated ROS generation, which are some of the primary markers for AD brains.</div></div><div><h3>Objectives</h3><div>The current research was intended to elucidate the chemical interaction of β-pinene against potential targets and evaluate its neuroprotective potential in ICV-STZ-induced sAD.</div></div><div><h3>Methodology</h3><div>The potential binding interactions of β-pinene and galantamine were evaluated against the active sites of PP2A, SOD1, catalase-3, and AChE using AutoDock vina. Additionally, the β-pinene and galantamine were subjected to tests of their ADMET by employing the Swiss ADME and Protox-II web servers. To assess the neuroprotective potential, β-pinene (50, 100, and 200 mg/kg) and galantamine (2 mg/kg) was administered p.o in ICV-STZ-treated wistar rats for 21 days. Moreover, behavioral parameters (NOR &amp; MWM), biochemical, AChE activities, and mitochondrial complexes were performed.</div></div><div><h3>Results</h3><div>Molecular docking study showed that β-pinene can interact with human PP2A, SOD1, Catalase-3, and AChE with better ligand efficiency as compared to galantamine. In-vivo data showed that β-pinene treatment (100, and 200 mg/kg) for 21 days exhibited significantly enhanced cognitive performance, as shown in behavioral studies. Additionally, β-pinene treatment significantly re-established antioxidant levels and mitochondrial capacities and attenuated altered AChE activity as compared to ICV-STZ-induced groups.</div></div><div><h3>Conclusions</h3><div><em>In-silico</em> studies revealed that β-pinene shared the same binding pocket as galantamine, supporting its neuroprotective effects in the ICV-STZ-induced animal model by alleviating oxidative stress and mitochondrial dysfunction and reducing AChE activity.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"991 ","pages":"Article 177307"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014299925000603","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Alzheimer's disease (AD) is a leading cause of dementia, characterized by progressive neurodegeneration and cognitive dysfunction. The disease aetiology is closely associated with proteinopathies, mitochondrial abnormalities, and elevated ROS generation, which are some of the primary markers for AD brains.

Objectives

The current research was intended to elucidate the chemical interaction of β-pinene against potential targets and evaluate its neuroprotective potential in ICV-STZ-induced sAD.

Methodology

The potential binding interactions of β-pinene and galantamine were evaluated against the active sites of PP2A, SOD1, catalase-3, and AChE using AutoDock vina. Additionally, the β-pinene and galantamine were subjected to tests of their ADMET by employing the Swiss ADME and Protox-II web servers. To assess the neuroprotective potential, β-pinene (50, 100, and 200 mg/kg) and galantamine (2 mg/kg) was administered p.o in ICV-STZ-treated wistar rats for 21 days. Moreover, behavioral parameters (NOR & MWM), biochemical, AChE activities, and mitochondrial complexes were performed.

Results

Molecular docking study showed that β-pinene can interact with human PP2A, SOD1, Catalase-3, and AChE with better ligand efficiency as compared to galantamine. In-vivo data showed that β-pinene treatment (100, and 200 mg/kg) for 21 days exhibited significantly enhanced cognitive performance, as shown in behavioral studies. Additionally, β-pinene treatment significantly re-established antioxidant levels and mitochondrial capacities and attenuated altered AChE activity as compared to ICV-STZ-induced groups.

Conclusions

In-silico studies revealed that β-pinene shared the same binding pocket as galantamine, supporting its neuroprotective effects in the ICV-STZ-induced animal model by alleviating oxidative stress and mitochondrial dysfunction and reducing AChE activity.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
β-蒎烯通过抗氧化、抗胆碱酯酶和线粒体保护作用改善ICV-STZ诱导的阿尔茨海默病病理:计算机和体内研究。
简介:阿尔茨海默病(AD)是痴呆症的主要原因,其特征是进行性神经变性和认知功能障碍。该疾病的病因与蛋白质病变、线粒体异常和ROS生成升高密切相关,这是AD大脑的一些主要标志。目的:本研究旨在阐明β-蒎烯与潜在靶点的化学相互作用,并评估其在icv - stz诱导的sAD中的神经保护作用。方法:利用Autodock vina检测β-蒎烯和加兰他明对PP2A、SOD1、过氧化氢酶-3和AChE活性位点的潜在结合作用。此外,利用瑞士ADME和Protox-II网络服务器对β-蒎烯和加兰他敏进行ADMET测试。为了评估其神经保护作用,在icv - stz治疗的wistar大鼠中,分别给药β-蒎烯(50、100和200 mg/kg)和加兰他敏(2 mg/kg) 21天。此外,还进行了行为参数(NOR和MWM)、生化、AChE活性和线粒体复合物的测定。结果:分子对接研究表明,β-蒎烯能与人PP2A、SOD1、过氧化氢酶-3和AChE相互作用,配体效率优于加兰他明。体内数据显示,在行为学研究中,β-蒎烯治疗(100和200 mg/kg) 21天后,认知能力显著提高。此外,与icv - stz诱导组相比,β-蒎烯处理显著地重建了抗氧化水平和线粒体能力,并减弱了改变的AChE活性。结论:计算机实验表明,β-蒎烯与加兰他敏具有相同的结合口袋,通过减轻氧化应激和线粒体功能障碍,降低AChE活性,支持其在icv - stz诱导的动物模型中的神经保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
572
审稿时长
34 days
期刊介绍: The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.
期刊最新文献
Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics Colchicine acutely reduces liver-secreted inflammatory and metabolic proteins in blood Integrative Mendelian randomization and experimental validation unveil novel druggable targets in primary biliary cholangitis 6-Shogaol ameliorates experimental colitis and colitis-associated colorectal cancer in mice through the Nrf2-Keap1 signaling pathway Cinnamaldehyde ameliorates diabetic kidney disease via anti-inflammatory effects: Bridging traditional use and molecular mechanisms
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1